3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Diseases
1
Kidney Neoplasms
1
Esophageal Neoplasms
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
Nivolumab
21
cabozantinib
12
Specimen Handling
11
Ipilimumab
10
belzutifan
9
pembrolizumab
8
Magnetic Resonance Spectroscopy
8
CTLA-4 Antigen
5
Biopsy
5
Axitinib
5
lenvatinib
4
Sunitinib
4
Immunoglobulin G
3
Disulfides
3
zimberelimab
2
tivozanib
2
relatlimab
2
pazopanib
2
palbociclib
2
atezolizumab
2
aldesleukin
2
X-Rays
2
Watchful Waiting
2
Radiosurgery
2
Nephrectomy
2
Bevacizumab
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
zimberelimab
×
30 days
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT05536141
2026-06-01
ARC-20
Arcus Biosciences, Inc.
Phase 1
Recruiting
362 enrolled